|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SCAMP5 |
Gene summary for SCAMP5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SCAMP5 | Gene ID | 192683 |
| Gene name | secretory carrier membrane protein 5 | |
| Gene Alias | SCAMP5 | |
| Cytomap | 15q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0001816 | UniProtAcc | A0A0A8K8F5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 192683 | SCAMP5 | HCC1_Meng | Human | Liver | HCC | 4.34e-32 | 6.29e-02 | 0.0246 |
| 192683 | SCAMP5 | S014 | Human | Liver | HCC | 3.16e-16 | 5.21e-01 | 0.2254 |
| 192683 | SCAMP5 | S015 | Human | Liver | HCC | 1.20e-14 | 5.36e-01 | 0.2375 |
| 192683 | SCAMP5 | S016 | Human | Liver | HCC | 1.35e-17 | 5.32e-01 | 0.2243 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003497612 | Liver | HCC | response to endoplasmic reticulum stress | 189/7958 | 256/18723 | 1.43e-24 | 4.06e-22 | 189 |
| GO:003010021 | Liver | HCC | regulation of endocytosis | 117/7958 | 211/18723 | 9.56e-05 | 8.32e-04 | 117 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SCAMP5 | insertion | In_Frame_Ins | novel | c.27_28insTGGGTAGGACATGACAGTGAGCATAGCGTGGATGGCCCT | p.Pro9_Pro10insTrpValGlyHisAspSerGluHisSerValAspGlyPro | p.P9_P10insWVGHDSEHSVDGP | Q8TAC9 | protein_coding | TCGA-BH-A0E7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| SCAMP5 | SNV | Missense_Mutation | c.425G>A | p.Gly142Glu | p.G142E | Q8TAC9 | protein_coding | tolerated(0.29) | benign(0.438) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR | |
| SCAMP5 | SNV | Missense_Mutation | c.509N>A | p.Ser170Asn | p.S170N | Q8TAC9 | protein_coding | tolerated(0.33) | benign(0.073) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD | |
| SCAMP5 | SNV | Missense_Mutation | c.139N>G | p.Asn47Asp | p.N47D | Q8TAC9 | protein_coding | tolerated(0.64) | benign(0.015) | TCGA-AA-A03J-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SCAMP5 | SNV | Missense_Mutation | c.190N>A | p.Gly64Arg | p.G64R | Q8TAC9 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
| SCAMP5 | SNV | Missense_Mutation | rs769826771 | c.673G>A | p.Ala225Thr | p.A225T | Q8TAC9 | protein_coding | tolerated(1) | benign(0.168) | TCGA-AY-A69D-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SCAMP5 | SNV | Missense_Mutation | rs779571294 | c.440C>T | p.Ser147Leu | p.S147L | Q8TAC9 | protein_coding | tolerated(0.08) | benign(0.007) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SCAMP5 | SNV | Missense_Mutation | rs368193195 | c.116G>A | p.Arg39His | p.R39H | Q8TAC9 | protein_coding | tolerated(0.11) | probably_damaging(0.993) | TCGA-AJ-A8CT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SCAMP5 | SNV | Missense_Mutation | c.320C>T | p.Ala107Val | p.A107V | Q8TAC9 | protein_coding | tolerated(1) | possibly_damaging(0.856) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SCAMP5 | SNV | Missense_Mutation | rs369019651 | c.502G>A | p.Ala168Thr | p.A168T | Q8TAC9 | protein_coding | tolerated(0.09) | benign(0.021) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |